Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | BHMT | Q93088 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274837 | 0.83 | TSHR (0.65) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL28696 | 0.82 | LMNA (1.00) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL28962323 | 0.82 | LMNA (1.00) | LMNAHSD17B10KMT2ATDP1TSHR | |
| SCHEMBL10397252 | 0.79 | LMNA (0.39) | LMNAHSD17B10KMT2ATDP1ALDH1A1 | |
| SCHEMBL11262277 | 0.79 | LMNA (0.64) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL9715444 | 0.79 | LMNA (0.93) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL11415832 | 0.79 | LMNA (0.93) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL21494504 | 0.79 | LMNA (0.93) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL5170829 | 0.79 | LMNA (0.93) | LMNAHSD17B10KMT2ATDP1TSHR | |
| E388 SCHEMBL9715431 | 0.79 | LMNA (0.93) | LMNAHSD17B10KMT2ATDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614066-B1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-11-29 | — | — | EP | claimed |
| EP-2614066-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2013-07-17 | — | — | EP | claimed |
| WO-2012032040-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-03-15 | — | — | WO | claimed |
| US-20070093465-A1 | Cephem compound | DSM IP ASSETS B.V. (NL) | 2007-04-26 | — | — | US | claimed |
| EP-1658296-A1 | CEPHEM COMPOUND | DSM IP Assets B.V. (NL) | 2006-05-24 | — | — | EP | claimed |
| WO-2004106347-A1 | CEPHEM COMPOUND | DSM IP ASSETS B.V. (NL) | 2004-12-09 | — | — | WO | claimed |
| US-6803460-B2 | ACIDIFICATION; CARBONATION | DSM IP ASSETS B.V. (NL) | 2004-10-12 | — | — | US | claimed |
| US-20030139595-A1 | Novel process for the fermentative production of cephalosporin | DSM IP ASSETS B.V. (NL) | 2003-07-24 | — | — | US | claimed |
| US-6552185-B1 | Acidifying and/or contacting with carbon dioxide followed by adsorption chromatography | DSM N.V. (NL) | 2003-04-22 | — | — | US | claimed |
| EP-1066294-B1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM NV (NL) | 2002-10-30 | — | — | EP | claimed |
| EP-1066294-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 2001-01-10 | — | — | EP | claimed |
| WO-1999050271-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 1999-10-07 | — | — | WO | claimed |
| WO-1998048037-A1 | A METHOD FOR CONTROLLING THE SOLUBILITY OF A β-LACTAM NUCLEUS | DSM N.V. (NL) | 1998-10-29 | — | — | WO | claimed |
| EP-2614066-B1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-11-29 | — | — | EP | disclosed |
| EP-2614066-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032040-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-03-15 | — | — | WO | disclosed |
| US-4196291-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1980-04-01 | — | — | US | disclosed |
| US-4141978-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-02-27 | — | — | US | disclosed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4001411-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139595-A1 | Novel process for the fermentative production of cephalosporin | ACSL6, ADSL, COASY | LMNA 2882/4885HSD17B10 124/4885KMT2A 3481/4885 |
| US-20070093465-A1 | Cephem compound | HCCS, PCCA, CPS1 | LMNA 1610/4885HSD17B10 23/4885KMT2A 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.